Niemeyer C, Hasenfuss G, Wais U, Knauf H, Schäfer-Korting M, Mutschler E
Eur J Clin Pharmacol. 1983;24(5):661-5. doi: 10.1007/BF00542218.
The pharmacokinetics of hydrochlorothiazide (HCT) was investigated in 23 subjects with normal renal function or widely varying degrees of renal failure. The half-life of elimination increased from 6.4 h in subjects with normal renal function to 11.5 h in patients with mild renal impairment (endogenous creatinine clearance between 30 and 90 ml/min), and to 20.7 h in patients with an endogenous creatinine clearance below 30 ml/min. The cumulative urinary excretion and the renal HCT clearance were correspondingly reduced in patients with impaired kidney function. In normal subjects HCT was mainly excreted by tubular secretion, but as renal HCT clearance in patients with renal impairment did not differ significantly from endogenous creatinine clearance, it was concluded that the secretory mechanism is most markedly impaired. In patients with an endogenous creatinine clearance of 30 to 90 ml/min, the dosage of HCT should be reduced to 1/2 and in patients with a endogenous creatinine clearance below 30 ml/min to 1/4 of the normal daily dose to avoid dose dependant side-effects.
在23名肾功能正常或肾功能衰竭程度差异很大的受试者中研究了氢氯噻嗪(HCT)的药代动力学。消除半衰期从肾功能正常的受试者的6.4小时增加到轻度肾功能损害患者(内生肌酐清除率在30至90 ml/min之间)的11.5小时,以及内生肌酐清除率低于30 ml/min的患者的20.7小时。肾功能受损患者的累积尿排泄量和肾脏HCT清除率相应降低。在正常受试者中,HCT主要通过肾小管分泌排泄,但由于肾功能损害患者的肾脏HCT清除率与内生肌酐清除率无显著差异,得出分泌机制受损最明显的结论。内生肌酐清除率为30至90 ml/min的患者,HCT剂量应减至正常日剂量的1/2,内生肌酐清除率低于30 ml/min的患者应减至1/4,以避免剂量依赖性副作用。